SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Select Sector SPDR Trust (The) - State Street Consumer Staples Select Sector SPDR ETF

Consumer Staples Select Sector SPDR Fund

A rotation into defensive consumer staples amid weakness in tech and AI-related shares is driving attention, with traders highlighting XLPs rebound from support and move to fresh highs. Some see the rally continuing, while others warn the trade is crowded and stretched, raising concerns about a pullback.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs October delivery growth is drawing attention, with traders debating whether the stronger month-over-month pace can support its ambitious fourth-quarter delivery outlook. The reaction is cautious: some see evidence of a growth rebound, while others worry that execution and weak Chinese EV sentiment could keep pressure on the shares.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians better-than-expected third-quarter results and raised delivery outlook, supported by the R2 ramp, are driving discussion. Bulls see improving execution and a possible recovery, while skeptics point to continued cash burn and a muted share-price reaction despite the strong report.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circles CFO plans to step down, and co-founder Sean Neville has resigned from the board, prompting concern about leadership stability as shares fall. Traders are split between viewing the departures as a warning sign and an orderly transition, while also debating USDC growth and competition.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is drawing attention amid a sharp, thinly traded pullback, with traders debating whether broad biotech weakness or concerns about CEO share sales, potential dilution, and uncertainty around the planned fourth-quarter CAN-2409 prostate-cancer BLA are weighing on sentiment. Bulls are focused on the filing and upcoming SITC data presentations, while skeptics question managements transparency and the regulatory timeline.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

Almonty is drawing attention amid a sharp, volatile pullback, with traders debating whether the weakness reflects broader market pressure or doubts about the Sangdong mines production ramp and near-term sales. Bullish voices point to tungstens tight-supply outlook and the mines move into production, while others want clearer evidence of steady output and revenue.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is selling off after quarterly results renewed concern about weaker underlying trading activity, with traders arguing that headline profit was largely supported by gains on crypto holdings; the Binance hack and broader crypto-market weakness added pressure. The community is split between viewing the decline as a buying opportunity and expecting further downside amid security and confidence concerns.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs steep selloff toward multiyear lows has traders focused on the lack of signed AI/data-center tenants and uncertainty around the Long Ridge project, alongside its sensitivity to Bitcoin and concerns about debt, dilution, and management execution. Some traders see the shares as oversold and are buying the dip, while others expect further losses without concrete lease or project updates.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is drawing attention around bullish analyst actions and product momentum tied to its AI-driven cybersecurity push, including new autonomous-security offerings discussed at its OneCon conference. Traders see rising AI-enabled cyber threats and the stocks valuation discount to peers as potential tailwinds, while takeover talk remains speculation and some remain cautious about execution and volatility.

Sterling Infrastructure, Inc. engages in the provision of construction solutions. It operates through the following segments: Transportation Solutions, E-Infrastructure Solutions, and Building Solutions. The Transportation Solutions segment provides infrastructure and rehabilitation services for highways, roads, bridges, airports, ports, light rail systems, water and wastewater facilities, and storm drainage systems. The E-Infrastructure Solutions segment develops advanced, large-scale site development systems and services for data centers, e-commerce distribution centers, warehousing facilities, transportation projects, energy infrastructure, and other specialized developments. The Building Solutions segment provides residential and commercial concrete foundation services for single-family and multi-family homes, as well as parking structures, elevated slabs, and other concrete construction projects. The company was founded in 1955 and is headquartered in The Woodlands, TX.

Sterling Infrastructure Inc

Sterling Construction Company, Inc.

Sterlings strong Q3 results and raised full-year outlook are colliding with a sharp selloff, leaving traders questioning why the stock is falling despite the beat. The debate centers on whether high expectations, margin pressure from the CEC acquisition, and a dip in signed backlog outweigh continued data-center demand and substantial unsigned awards; some see profit-taking or broader weakness in AI-infrastructure stocks instead.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Moleculin Biotech (MBRX) Upgraded to Buy: Here's Why

Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Moleculin Biotech Stock Is Sinking Friday: What's Going On?

Moleculin Biotech updates MIRACLE trial for AML and prices a $9.3M offering at $0.75, driving MBRX shares down 63%. Read full data.read more...

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers

Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session.
Moleculin Biotech (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of theirread more...

MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance

Equity

The drop follows four straight days of the stock closing in the green.


Scalable Biotech Manufacturing Unlocks a $14B Market

Scalable Biotech Manufacturing Unlocks a $14B Market Scalable Biotech Manufacturing Unlocks a $14B Market PR Newswire VANCOUVER, BC, March 27, 2026 Issued on behalf of Ava Bio, Inc.VANCOUVER, BC, March 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary The global cell therapy manufacturing...

Why Did MBRX Stock Climb 14% Today?

Moleculin Biotech said on Wednesday that it is on track to treat the 45th patient with Annamycin as part of its Miracle study.

Why Did MBRX Stock Plummet Over 25% Today?

Moleculin Biotech will implement a 1-for-25 reverse stock split of its common stock, effective December 1.

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions PR Newswire VANCOUVER, Oct. 21, 2025 Equity...

Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know

Moleculin Biotech Gets EMA Nod For Leukemia Trial: Retail Feels Bullish On ‘Low And Slow’ Setup 

The trial, which will involve sites in the U.S., Europe, and the Middle East, aims to combine Phase 2B and Phase 3 data for efficacy evaluation of the Miracle trial of Annamycin for relapsed or refractory acute myeloid leukemia.

This account has been verified as an official MBRX representative.

Verified Account

Moleculin Biotech

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe in July 2015 and is headquartered in Houston, TX.

Moleculin Biotech Inc

Bullish Sentiment

<ul class="summary-bullets"><li>The company said the independent safety board reviewing the study saw a clear trend favoring the Annamycin combination, though there was no statistical significance.&nbsp;</li><li>Full data from the first part of the trial is expected in the second half of 2026.</li><li>Retail traders raised concerns pertaining to the study’s sample size and the company’s cash position.</li></ul>Shares of Moleculin Biotech (MBRX) plunged more than 25% on Tuesday after the company announced interim data from its mid-to-late stage clinical trial for Annamycin in relapsed or refractory acute myeloid leukemia (AML), which did not achieve statistical significance. &nbsp;The drop follows four straight days of the stock closing in the green. The stock is now on track for its worst day since February.<h2 class="st-heading-2">What The Results Showed</h2>In the first 45 patients treated in the ongoing MIRACLE trial, Annamycin combined with high-dose chemotherapy produced complete remission rates of 36% to 43% in two different dose arms, the company said. This was roughly three times higher than the 12% remission rate seen in patients who received standard chemotherapy alone.The company said the independent safety board reviewing the study saw a clear trend favoring the Annamycin combination, though there was no statistical significance, and recommended continuing the trial without changing the doses being tested.<h2 class="st-heading-2">Trial Status And Next Steps</h2>The MIRACLE study is still ongoing. So far, 67 of the planned 90 patients in this first part of the trial have been enrolled. Moleculin said it will continue adding patients to determine the best dose before moving to the next stage of the study.Full data from the first part of the trial is expected in the second half of 2026. The final analysis for the two-part trial is scheduled for 2028.CEO Walter Klemp called the early results encouraging, noting that many of the patients had already failed previous treatments, including newer therapies.The company emphasized that more data from additional patients is still needed before any final conclusions can be drawn.<h2 class="st-heading-2">How Did MBRX Retail Traders React?</h2>On Stocktwits, retail sentiment around MBRX stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user raised doubts as to how the company will secure money to fund the study. MBRX had $10.317 million in cash and cash equivalents at the end of its latest reported quarter, which ended March. The company said that it expects its funds to suffice for planned operations into the third quarter of 2026.<stembedurl>https://www.stocktwits.com/stockmathy/message/657907026</stembedurl>Another user opined that “a partnership would be a great leg up for MBRX.” They further added that big pharma players, including Pfizer and Sanofi, should have the company on their radar.<stembedurl>https://www.stocktwits.com/LIT_L7/message/657904757</stembedurl>A third user noted that the sample size for the interim data readout was too small to create confidence.<stembedurl>https://www.stocktwits.com/ezMoney001/message/657892312</stembedurl><a href="https://stocktwits.com/symbol/MBRX">MBRX stock</a> has fallen about 20% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/srpt-stock-climbs-after-sarepta-seeks-permanent-fda-nod-for-two-duchenne-therapies/cZ1QVbSR70Q">SRPT Stock Climbs After Sarepta Seeks Permanent FDA Nod For Two Duchenne Therapies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Moleculin Biotech logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The drop follows four straight days of the stock closing in the green.

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$7.90
Prev Close	$8.72
Open	$8.80
Dividend Yield	0.00%
50-Day Moving Average	$10.84
Beta	0.85
Avg. Volume	61,036.72
PE Ratio	-0.02

52-Week High	$315.00
52-Week Low	$3.23
Market Capitalization	$8.29M
EPS (Annual)	-$568.38
Price to Book	0.24
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

MBRX Fundamentals